Actividades asistenciales

HAND AND WRIST REHABILITATION UNIT WITH SOFT ACTUATOR

11/06/2026 - The invention relates to a wrist rehabilitation unit (1) for providing hand (E) rehabilitation. Accordingly, the innovation is that to adapt to different wrist structures, it comprises at least...

INTEGRATED HAND AND WRIST REHABILITATION PLATFORM

11/06/2026 - The invention relates to a rehabilitation platform (1) for the rehabilitation of patients' hands and wrists. The innovation is that it comprises at least one main unit (10) with at least one...

SYSTEM AND METHOD FOR MAGNETIC DRUG DELIVERY USING A 3D NESTED ANTI-HELMHOLTZ CAGE

11/06/2026 - A system for magnetic drug delivery is disclosed, featuring a 3D nested anti-Helmholtz cage configuration. The system comprises an outer cage for generating a primary magnetic field gradient over...

Knee brace hinge mechanism

01/06/2026 - Przedmiotem zgłoszenia jest mechanizm zawiasowy ortezy stawu kolanowego zbudowany z komponentu udowego i komponentu piszczelowego połączonych zawiasowo za pomocą sworznia, który...

RECOMBINANT EXPRESSION SYSTEMS AND RADIATION USEFUL FOR THE TREATMENT OF CANCER

25/06/2026 - Recombinant expression systems and radiation useful for the treatment of cancer The invention relates to a recombinant expression system comprising a nucleic acid construct, particularly for use...

S100A1 PROTEIN-DERIVED PEPTIDE FOR USE IN TREATING CANCER OR IN TREATING OR PREVENTING ANTINEOPLASTIC AGENT-MEDIATED CYTOTOXICITY, CANCER THERAPY-RELATED CARDIAC DYSFUNCTION OR CANCER THERAPY RELATED HEART FAILURE

25/06/2026 - The present invention pertains to a peptide of the S100A1 protein for use in the treatment or prevention of antineoplastic agent-mediated cytotoxicity or cancer therapy-related cardiac dysfunction...

INHIBITORY COMPOUNDS

25/06/2026 - The present invention relates to certain compounds that function as inhibitors of DHX9 activity (RNA Helicase A / RHA or Nuclear DNA Helicase II / NDH II). The present invention also relates to...

COMBINATION THERAPIES USING CDK4 INHIBITORS WITH PD-1 AXIS BINDING ANTAGONISTS

25/06/2026 - This invention relates to, in part, a method for treating cancer by administering a CDK4 inhibitor in combination with a PD-1 axis binding antagonist, and optionally an CDK2 inhibitor to a subject...

EGFR INHIBITOR-FUNCTIONALIZED ALBUMIN-BINDING PLATINUM COMPOUNDS FOR CANCER THERAPY

25/06/2026 - The present invention relates to novel EGFR inhibitor-functionalized albumin-binding platinum compounds of formula (I), including in particular EGFR inhibitor-functionalized albumin-binding...

CD70-TARGETED CARS AND ENGINEERED CELLS COMPRISING SAME AND RELATED METHODS

25/06/2026 - [0000] Provided herein are CD70-targeted chimeric antigen receptors (CARs), genetically engineered cells such as T cells containing the same, and related methods and uses of the genetically...

KAT6 TARGETING COMPOUNDS

25/06/2026 - The present disclosure provides bifunctional compounds comprising a target protein binding moiety and a E3 ubiquitin ligase binding moiety, and associated methods of use.

THERAPEUTIC USES OF HER-2 TARGETED BISPECIFIC POLYPEPTIDES

25/06/2026 - Provided are compositions and methods for treating cancers, in particular those characterized with HER2 expression. The compositions include a conditionally-activatable XTENylated...

MULTISPECIFIC MOLECULES BINDING TRAILR2 AND CDH17 AND USES THEREOF

25/06/2026 - The present application provides multispecific antigen-binding proteins (e.g., antibodies) that specifically bind TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and cadherin 17...

CANCER THERAPY OF SUBJECTS CARRYING MUTATIONS IN A SPLICING FACTOR GENE

25/06/2026 - The present invention is directed to SEL24/MEN1703 for use in the treatment of a patient suffering from cancer and/or for use in increasing the overall survival of a patient suffering from cancer,...

AXL INHIBITORS FOR THE TREATMENT OF MASTOCYTOSIS

25/06/2026 - Mastocytosis is a rare and heterogeneous disorder marked by the abnormal accumulation of mast cells (MCs) in various tissues. Tyrosine kinase inhibitors have shown limited efficacy, suggesting...

FUSED AZINES FOR THE TREATMENT OF CANCER

25/06/2026 - The present invention discloses compounds according to Formula I: [Formula I] I wherein A, B, X1, X2, X3, Y, L1, R1, R2, R3, R4, R5, R6, n, p, and q are as defined herein. The present invention...

COMBINATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND ANTI-TROP2 ANTIBODY-DRUG CONJUGATE

25/06/2026 - A pharmaceutical product for administration of an anti- HER2 antibody-drug conjugate (ADC) in combination with an anti-TROP2 ADC is provided. The anti-HER2 ADC and the anti-TROP2 ADC comprise a...

THERAPEUTIC STRATEGY FOR TREATING COPPER-MEDIATED PATHOLOGIES

25/06/2026 - The present invention is directed to a novel therapeutic strategy for treating a disease mediated by copper, by inhibiting the function of cellular prion protein (PrP).

COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED MOLECULES TARGETING NECTIN-4 AND EFFECTOR CELL ANTIGENS

25/06/2026 - Disclosed herein are polypeptides and polypeptide complexes that are capable of binding tumor cell antigens and effector cell antigens. In some embodiments, the polypeptides and polypeptide...

ENT1 INHIBITORS IN COMBINATION WITH CAR-T CELL THERAPY

25/06/2026 - Disclosed herein are combinations, methods, and uses comprising administering an ENT1 inhibitor and a CAR-T cell therapy for the treatment of a disease. In some embodiments, the disease is...

SOLID FORMS COMPRISING AN AMPA POSITIVE ALLOSTERIC MODULATOR

25/06/2026 - Solid forms comprising 9-(4-(cyclohexyloxy)phenyl)-7-methyl-3,4-dihydropyrazino[2,1-c][1,2,4]thiadiazine 2,2-dioxide (Compound (I)), compositions comprising the same, and methods of making and...